All of the following statements about Exenatide are true except: (A) It is a GLP-1 analogue, (B) It can be used for treatment of type 1 diabetes mellitus, (C) It is given subcutaneously, (D) It decreases glucagon
Answer is B. Refer CMDT 2010 p1095 Exenatide is a GLP-1 receptor agonist that is more resistant to DPP-4 action band cleared by the kidney When this drug bus given to patients with type 2 diabetes by subcutaneous injection twice daily Exenatide appears to have the sane effects as GLP-1 on glucagon suppression and gastric emptying